Generic Firms Want Looser Bioequivalence, But Change May Be Difficult For FDA
Executive Summary
Sponsors contend that changes to bioequivalence guidances in the middle of a review cycle have delayed approvals; FDA says rule changes might be difficult because of existing regulations.
You may also be interested in...
Complex Generics: US FDA Heeds Some, But Not All, Of Industry’s Calls For Flexibility On Transdermal Products
Revised draft guidance suggests greater openness to alternative methods and scales for measuring adhesion, but agency sticks with 15% non-inferiority margin despite manufacturer objections; FDA also releases new guidance on assessing irritation and sensitization potential with topical delivery system products.
Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action
Other proposals were broad in nature, and did not provide the agency with specific mechanisms to consider.
Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action
Other proposals were broad in nature, and did not provide the agency with specific mechanisms to consider.